NYSE: NVTAInvitae Corp Stock
$1.21-0.10 (-7.63%)
Updated Mar 20, 2023
NVTA Price
$1.21
Fair Value Price
N/A
Market Cap
$297.94M
52 Week Low
$1.18
52 Week High
$9.18
P/E
-0.09x
P/B
2.93x
P/S
0.85x
PEG
N/A
Dividend Yield
N/A
Revenue
$516.30M
Earnings
-$3.11B
Gross Margin
19.2%
Operating Margin
-599.35%
Profit Margin
-601.6%
Debt to Equity
18.19
Operating Cash Flow
-$493M
Beta
2.3
Next Earnings
May 1, 2023
Ex-Dividend
N/A
Next Dividend
N/A
NVTA Overview
Invitae Corporation provides genetic tests with hereditary cancer, cardiology, neurology, pediatrics, oncology, metabolic conditions, and rare disease application, as well as digital health and health data services. Invitae was incorporated in 2010 and is headquartered in San Francisco, CA.
Zen Score
–
Industry Average (30)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how NVTA scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
NVTA is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
NVTA is good value based on its book value relative to its share price (2.93x), compared to the US Diagnostics & Research industry average (4.13x)
P/B vs Industry Valuation
NVTA is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more NVTA due diligence checks available for Premium users.
Be the first to know about important NVTA news, forecast changes, insider trades & much more!
NVTA News
Valuation
NVTA price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.09x
Industry
33.27x
Market
22.37x
NVTA price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
2.93x
Industry
4.13x
NVTA is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
NVTA's financial health
Profit margin
Revenue
$122.5M
Net Income
-$99.8M
Profit Margin
-81.5%
NVTA's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
NVTA's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$2.0B
Liabilities
$1.9B
Debt to equity
18.19
NVTA's short-term assets ($693.13M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
NVTA's long-term liabilities ($1.74B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
NVTA's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
NVTA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$82.0M
Investing
$121.9M
Financing
$599.0k
NVTA's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
NVTA vs Diagnostic & Research Stocks
Invitae Stock FAQ
©2023 WallStreetZen
Company
AboutBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.